AMENDMENTS TO THE CLAIMS

1. (currently amended) Compound of the structural formula I:

Formula I



and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C_1-C_8 alkyl, substituted C_1-C_8 alkyl, aryl-C_{0-4}-alkyl, substituted aryl-C_{0-4}-alkyl, C_3–C_6 cycloalkyl, substituted C_3–C_6 cycloalkyl, heteroaryl-C_{0-4}-alkyl, substituted heteroaryl-C_{0-4}-alkyl, C_3-C_6 cycloheteroalkylaryl-C_{0-2}-alkyl, substituted C_3-C_6 cycloheteroalkylaryl-C_{0-2}-alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl and substituted C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl; wherein the substituents for said substituted alkyl, arylalkyl,cycloalkyl, heteroarylalkyl, cycloheteroalkylarylalkyl,and cycloalkylarylalkyl are from one to three substituents each independently selected from R1';

(b) R1', R3', and R4' ~~and R19'~~ are each independently selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, nitro, cyano, CHO, hydroxyl, arylC_0-$C5_5$alkoxy, arylC_0-$C5_5$alkyl, alkylcarboxamido and COOH;

~~(c) X is an optionally substituted C_1-C_5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S;~~

~~(d)~~ (c) Y is C, O, S, NH or a single bond; ~~and~~

(d)m is 0, 1, or 2; and

(e) R21 is selected from the group consisting of phenyl, substituted phenyl, and C_1-C_6 alkyl.

~~(e) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, and $(CH_2)_n$-COOR19; wherein said $(CH_2)_n$-COOR19 is optionally substituted with a group selected from C_1-C_5 alkyl, arylC_0-C_5alkoxy, and arylC_0-C_5alkyl; and wherein~~

~~(i) n is 0, 1, 2 or 3,~~

~~(ii) A is selected from the group consisting of carboxyl, C_1-C_3alkylnitrile, carboxamide, sulfonamide, substituted sulfonamide, acylsulfonamide, substituted acylsulfonamide, tetrazole and substituted tetrazole;~~

~~(iii) R3 is selected from the group consisting of H, C_1-C_5 alkyl, and~~ C_1-~~C_5 alkoxy, wherein said alkyl and alkoxy are each optionally substituted with from one to three substituents each independently selected from R3';~~

~~(iv) R4 is selected from the group consisting of H, halo, C_1-C_5 alkyl, C_1-C_5 alkoxy, C_3-C_6 cycloalkyl, aryl C_0-C_4 alkyl, and arylC_0-C_2alkoxy, or R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein said alkyl, alkoxy, cycloalkyl, arylalkyl, and arylalkoxy are each optionally substituted with from one to three substituents each independently selected from R4'; and~~

~~(f) R19 is selected from the group consisting of hydrogen, arylmethyl, and C1-C4alkyl, wherein said arylmethyl and C1-C4alkyl, are each optionally substituted with from one to three substituents each independently selected from R19'.~~

2. (canceled).

3. (canceled).

4. (canceled).

2 ~~5.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims 1~~,~~ ~~2, 3 or 4~~ wherein R6 is selected from the group consisting of hydrogen, substituted C_1-C_4 alkyl, C_1-C_4 alkyl, substituted aryl-C_{0-4}-alkyl, and aryl-C_{0-4}-alkyl.

6. (canceled).

7. (canceled).

8. (canceled).

3 ~~9.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims 1~~,~~ ~~2, 3, 4, 5, 6, or 7~~ wherein Y is C.

10. (canceled).

4 ~~11.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims 1~~,~~ ~~3, 5, 8,~~ or Claim 3 ~~9, or 10~~ wherein aryl is substituted phenyl.

5 ~~12.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 11~~ 4 wherein R2 is hydrogen and R1 is substituted phenyl.

6 ~~13.~~ (original) A compound as claimed by Claim 1 or 5 ~~12~~ wherein substituted phenyl is substituted with a group selected from aryl, aryloxy, and arylalkyloxy.

14. (canceled).

15. (canceled).

7 ~~16.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims 4 ~~11 through 15~~ wherein the ~~E~~ $CO_2C((CH_3)(OR21))$-Y group is in the para position in relation to the X linker.

8 ~~17.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 10, Claim 14, Claim 15, or~~ Claim 7 ~~16~~ wherein R1 is selected from unsubstituted phenyl and substituted phenyl, and R6 is hydrogen.

9 ~~18.~~ (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 17~~ 7 ~~16~~ wherein R1 is substituted phenyl wherein the phenyl substituent is one or two independently selected from the group consisting of CF_3, C_1-C_4 alkyl, and halo.

10 ~~19.~~ (Currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 18~~ Claim 9 ~~18~~ wherein R1 is substituted phenyl and R2 is hydrogen.

20. (canceled).

11 ~~21~~. (currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by ~~any one of~~ Claims 1-~~20~~.

12 ~~22~~. (currently amended) A method of modulating a peroxisome proliferator activated receptor, comprising the step of contacting the receptor with at least one compound as claimed by ~~any one of~~ Claims 1-~~20~~.

13 ~~23~~. (currently amended) A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal in need thereof, a therapeutically effective amount of at least one compound of Claims 1-~~20~~.

14 ~~24~~. (currently amended) A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal in need thereof, an effective amount of at least one compound of Claims 1-~~20~~.

15 ~~25~~. (currently amended) A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal in need thereof, a therapeutically effective amount of at least one compound of Claims 1-~~20~~.

26. (canceled).

16 ~~27~~. A compound of Claim 1 ~~as disclosed by any one of the examples herein.~~ selected from the group consisting of:


















Chiral


Chiral


Chiral
O
OH
O
N
H
N
O
H_3C
O


Chiral
O
OH
O
N
H
N
O
H_3C
O


Chiral
O
OH
O
N
H
N
O
H_3C
O


Chiral
O
OH
O
N
H
N
O
H_3C
O


Chiral
H_3C
O
OH
O
N
H
N
O
H_3C
O


Chiral
CH_3
O
OH
O
N
H
N
O
H_3C
O


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral
Na+


Chiral
Na+






















Chiral


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral










Chiral


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral


Chiral

Chiral



Chiral



Chiral



Chiral



Chiral



Chiral




Chiral
O
OH
O
O
O
N
H
N
O
O
H_3C